RESULTS: In our cohort, there were a total of 44 men with cancer who underwent CT with 85 post-chemo T levels. Mean age of the cohort was 41.3 years (Median [ 33.5, STD [ 18.5). Mean pre-CT total T (TT) level was 472AE 247 ng/dl. 70% of these men had testicular cancer, 9% had bladder cancer and 20% had other. By 6 months post-CT, 64% of patients did not yet have a normal TT level. However, by the 2-year mark, only 35% of patients did not yet demonstrate recovery. Kaplan-Meier analysis of time to normal T can be seen in Fig 1. CONCLUSIONS: In men with cancer who underwent chemotherapy, over 50% of men still do not have normal T levels post chemo at the 1 year post chemo timepoint. Our study shows the importance of following T levels in these patients post-chemo. Consideration should be given to offering testosterone therapy to those patients with LT. 
INTRODUCTION AND OBJECTIVES:
The safety of testosterone replacement therapy in men who have undergone radiation therapy (RT) for localized prostate cancer remains undefined.
METHODS: In a large national cohort, the Veterans Affairs Informatics and Computing Infrastructure, we identified node-negative and non-metastatic prostate cancer patients diagnosed between 2001-2015 treated with RT. We excluded patients for missing covariate and follow-up data. We then coded receipt of testosterone replacement after RP as a time-dependent covariate. Other covariates included: age, Charlson Comorbidity index, diagnosis year, body mass index, race, PSA, clinical T/N/M stage, Gleason score, and receipt of hormone therapy. Biochemical recurrence was defined as a post-RP PSA! 0.2. We evaluated prostate cancer-specific survival, overall survival, and biochemical recurrence free survival using multivariable Cox regression. RESULTS: Our cohort included 41,544 patients, of whom 544 (1.3%) received testosterone replacement after RT. There were no differences in Charlson comorbidity, clinical T stage, median pretreatment PSA or Gleason score between treatment groups. Testosterone patients were more likely to be of younger age, nonblack, have a lower median post-treatment PSA nadir (0.1 vs. 
The administration of exogenous testosterone (T) to men who have undergone radical prostatectomy (RP) for prostate cancer remains controversial. Besides small case series there are no large population, long-term studies assessing the safety of this treatment in this population. We have adopted a policy of allowing the decision regarding T therapy in men post-RP to be a negotiated one with a comprehensive discussion of the data and the pros and cons of T therapy. This prospective study was undertaken to define the safety of exogenous T therapy in men post-RP.
METHODS: Men were considered candidates for T therapy if (i) they had two early morning total T level <300 ng/dl (ii) had symptoms/signs of TD (iii) had pathologically organ-confined, Gleason 6-7 prostate cancer and (iv) an undetectable PSA level post-RP precommencement of T therapy. Once men opted for treatment they had labs tested 4 weeks later. T dose was titrated to achieve a serum level of 500-600ng/dl. Patients had serum T levels and PSA checked every 6 months.
RESULTS: A total of 360 patients have been prescribed T therapy to date. Mean age and pre-RP PSA levels were 59AE12 years and 4AE6 ng/dl respectively. Baseline total T levels were 228AE94 (80-296) ng/dl. 48% had a Gleason Score (GS) of 6, 42% had GS 7 disease. Median time post-RP before T therapy was commenced was 9 months (IQR 9, 112) months. 28% were using clomiphene, 56% transdermal T and 16% IM T to achieve therapeutic T levels. Mean post-treatment total T was 520AE280 (396-920) ng/dl. Median duration on T therapy at last follow-up was 38 (IQR 6, 112) months equating to mean duration post-RP of 66AE41 months. A single man had a PSA recurrence at a time point 2.5 years post-RP.
CONCLUSIONS: In this series of carefully selected patients (G 7, organ confined disease, post-RP undetectable PSA level)the administration of exogenous T for the treatment of TD appears to be safe 3 years post-T administration.
Source of Funding: None

MP58-14 TESTOSTERONE THERAPY IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER
